2025-03-31 18:34:49
Latest Post
NHPC commissions 3 units of Parbati-II HE project
ixigo announces APRIL FULL REFUND SALE for 1st April - 100 Lucky Travellers To Win 100% Refund on Flight Bookings
Engineers India Ltd receives orders worth Rs. 245 crores
Blue Star appoints Mohit Sud as Group President, Unitary Cooling Products 
Jyoti Ltd receives Rs. 108.17 crores IT demand notice for AY 2020-21
Stock Report
Jenburkt Pharmaceuticals posts Rs. 6.22 crore profit in Q3FY22
Posted On : 2022-02-12 14:27:39( TIMEZONE : IST )
JENBURKT PHARMACEUTICALS LTD. has reported Standalone financial results for the period ended December 31, 2021.
Financial Results (Q3 FY2022) - QoQ Comparison
The company has reported total income of Rs. 34.2871 crores during the period ended December 31, 2021 as compared to Rs. 36.6990 crores during the period ended September 30, 2021.
The company has posted net profit / (loss) of Rs. 6.2271 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs. 7.9704 crores for the period ended September 30, 2021.
The company has reported EPS of Rs. 13.57 for the period ended December 31, 2021 as compared to Rs. 17.37 for the period ended September 30, 2021.
| Financials | Q3 FY2022 | Q2 FY2022 | % Change |
| Total Income | ₹ 34.2871 crs | ₹36.6990 crs |  -6.57% |
| Net Profit | ₹6.2271 crs | ₹7.9704 crs | -21.87% |
| EPS | ₹13.57 | ₹17.37 | -21.88% |
Financial Results (Q3 FY2022) - YoY Comparison
The company has reported total income of Rs. 34.2871 crores during the period ended December 31, 2021 as compared to Rs.32.8690 crores during the period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.6.2271 crores for the period ended December 31, 2021 as against net profit / (loss) of Rs.5.9459 crores for the period ended December 31, 2020.
The company has reported EPS of Rs.13.57 for the period ended December 31, 2021 as compared to Rs.12.96 for the period ended December 31, 2020.
| Financials | Q3 FY2022 | Q3 FY2021 | % Change |
| Total Income | ₹ 34.2871 crs | ₹32.8690 crs |  4.31% |
| Net Profit | ₹6.2271 crs | ₹5.9459 crs | 4.73% |
| EPS | ₹13.57 | ₹12.96 | 4.71% |
Financial Results (9 Months Ended FY2022) - YoY Comparison
The company has reported total income of Rs.99.3608 crores during the 9 Months period ended December 31, 2021 as compared to Rs.82.7834 crores during the 9 Months period ended December 31, 2020.
The company has posted net profit / (loss) of Rs.18.8484 crores for the 9 Months period ended December 31, 2021 as against net profit / (loss) of Rs.12.6257 crores for the 9 Months period ended December 31, 2020.
The company has reported EPS of Rs.41.07 for the 9 Months period ended December 31, 2021 as compared to Rs.27.51 for the 9 Months period ended December 31, 2020.
| Financials | 9 Months Ended FY2022 | 9 Months Ended FY2021 | % Change |
| Total Income | ₹99.3608 crs | ₹82.7834 crs | 20.03% |
| Net Profit | ₹18.8484 crs | ₹12.6257 crs | 49.29% |
| EPS | ₹41.07 | ₹27.51 | 49.29% |
Shares of JENBURKT PHARMACEUTICALS LTD. was last trading in BSE at Rs. 551.15 as compared to the previous close of Rs. 556.45. The total number of shares traded during the day was 2203 in over 65 trades.
The stock hit an intraday high of Rs. 565.00 and intraday low of 540.00. The net turnover during the day was Rs. 1215989.00.
